C5 Complement Inhibitors Market Expected To Reach $14.93 Billion By 2030 As Growth Accelerates At 13.7% CAGR
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
C5 Complement Inhibitors Market Size Outlook: How Fast Will Revenue Grow Through 2030?
The market for c5 complement inhibitors has experienced significant expansion in recent years. Projections indicate an increase from $7.84 billion in 2025 to $8.93 billion in 2026, reflecting a compound annual growth rate (CAGR) of 13.9%. Several factors drove this historical growth, including the approval of pioneering complement inhibitors, a rising prevalence of diagnosed rare hematological conditions, heightened clinical understanding of complement pathways, the proliferation of specialized treatment facilities, and robust progress in biologic drug development programs.
The market for c5 complement inhibitors is anticipated to experience substantial expansion over the coming years. By 2030, its value is projected to hit $14.93 billion, reflecting a compound annual growth rate (CAGR) of 13.7%. Several factors are driving this forecasted growth, including a higher incidence of autoimmune and rare conditions, the broadening of tailored medicine strategies, a dynamic pipeline for next-generation inhibitors, enhanced capabilities for biologic manufacturing, and favorable regulatory frameworks for orphan drugs. Key developments shaping this period involve an increased uptake of targeted immunotherapies, broader application in uncommon complement-related diseases, a shift toward long-acting formulations, the emergence of combined therapeutic protocols, and a heightened emphasis on prompt diagnosis and early treatment.
Download A Free Sample Report For Comprehensive Market Insights:
C5 Complement Inhibitors Market Growth Drivers: What Factors Are Accelerating Expansion?
The growth of the C5 complement inhibitors market is anticipated to be driven by the rising frequency of chronic diseases. These conditions are long-term medical issues that develop gradually and persist, often demanding ongoing care and oversight to avert complications. Their increasing occurrence is primarily fueled by lifestyle factors like unhealthy eating, lack of exercise, smoking, and stress, which lead to progressive health decline. By inhibiting complement system overactivation, C5 complement inhibitors reduce inflammation, avert tissue harm, and enhance patient outcomes for diseases like PNH, aHUS, and other complement-linked disorders. As an illustration, the International Diabetes Federation, a nonprofit based in Belgium, reported in April 2025 that over 9.5 million individuals globally had type 1 diabetes in 2024, with 1.9 million being children and adolescents under 20. The worldwide diabetic population is projected to surge to 853 million by 2050. Consequently, the escalating prevalence of chronic diseases is propelling the expansion of the C5 complement inhibitors market.
C5 Complement Inhibitors Market Segment Landscape And Growth Potential
The c5 complement inhibitors market covered in this report is segmented –
1) By Product: Long Acting C5 Inhibitors, Short Acting C5 Inhibitors
2) By Drug: Eculizumab, Ravulizumab, Other Drugs
3) By Route Of Administration: Intravenous, Subcutaneous
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies
5) By Application: Paroxysmal Noctural Hemoglobuinuria, Atyptical Hemolytic Uremic Syndrome, Generalized Myasthenia Gravis, Neuromyelitis Optics Spectrum Disorder, Other Applications
Subsegments:
1) By Long Acting C5 Inhibitors: Crovalimab, Pozelimab, Tesidolumab, Other Long-Acting C5 Inhibitors
2) By Short Acting C5 Inhibitors: Zilucoplan, Cemdisiran, Nomacopan, Other Short-Acting C5 Inhibitors
C5 Complement Inhibitors Market Trends: What Is Shaping Future Industry Growth?
Key players in the C5 complement inhibitors market are prioritizing the development of innovative treatments, including self-administered C5 inhibitors, to broaden therapeutic options for generalized myasthenia gravis. These self-administered C5 inhibitors function as targeted therapies that inhibit the complement C5 protein, thereby reducing inflammation and immune-related tissue damage, and are intended for patient use in managing conditions like paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. A notable example occurred in October 2023, when Union Chimique Belge (UCB) SA, a biopharmaceutical firm headquartered in Belgium, received approval from the U.S. Food and Drug Administration (FDA), a federal regulatory body, for Zilbrysq (zilucoplan) to treat adults with generalized myasthenia gravis (gMG). This authorization is limited to patients who test positive for anti-acetylcholine receptor (AChR) antibodies, a prevalent subtype of the disorder. As a once-daily, subcutaneous C5 complement inhibitor that can be self-administered, Zilbrysq introduces a novel therapeutic alternative for individuals with gMG. This regulatory success enhances UCB’s neurology pipeline, giving patients with autoimmune neuromuscular conditions greater access to diverse treatment options.
C5 Complement Inhibitors Market Competitive Landscape: Who Are The Leading Companies?
Major companies operating in the c5 complement inhibitors market are AstraZeneca plc, F. Hoffmann-La Roche AG, Chugai Pharmaceutical Co. Ltd., Swedish Orphan Biovitrum AB, Alnylam Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Omeros Corporation, Dianthus Therapeutics Inc., Akari Therapeutics Plc, Regeneron Pharmaceuticals Inc., UCB Pharma SA, Astellas Pharma Inc., InflaRx NV, Alexion Pharmaceuticals Inc., Ra Pharmaceuticals Inc., ChemoCentryx Inc., Annexon Biosciences Inc., Iveric Bio Inc., Apellis Pharmaceuticals Inc., Kira Pharmaceuticals Inc.
Access The Complete C5 Complement Inhibitors Market Report:
C5 Complement Inhibitors Market Global Footprint: Which Region Holds Market Leadership?
North America was the largest region in the C5 complement inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the c5 complement inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
